Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]

Ferrufino CP, Munakata J, Wei W, et al. *Clinicoecon Outcomes Res.* 2018;10: 805—819.

On page 817, Table S2, the monitoring costs for (A) csDMARD-IR and (B) TNF-IR were changed. The updated table is as follows:

On page 810, Table 4, Drug costs column, Methotrexate, the Unit WAC was listed as \$1 however it should have been \$2.36. The updated table is as follows:

Table 4 Drug cost summary

Drug costs	Dose	Package size	WAC	Unit WAC	Annual cost ^a	Annual price increase ^b	Net WAC with ICER specified discounts ^c
Non-TNFi biologics							
Abatacept (SC)	125.0 mg	4 syringes	\$4,131	\$1,033	\$57,359	13.5%	\$2892
Abatacept (IV)	250.0 mg	1 vial	\$1,046	\$1,046	\$49,906	13.5%	\$732
Rituximab (IV)	100.0 mg	1 vial	\$835	\$835	\$50,863	5.0%	\$710
Sarilumab (SC)	150.0 mg	2 syringes	\$3,159	\$1,580	\$43,317	5.3%	\$2,527
Sarilumab (SC)	200.0 mg	2 syringes	\$3,159	\$1,580	\$41,208	5.3%	\$2,527
Tocilizumab (SC)	162.0 mg	1 syringe	\$985	\$985	\$40,117	8.4%	\$788
Tocilizumab (IV)	80.0 mg	1 vial	\$417	\$417	\$39,038	6.3%	\$333
TNFi biologics							
Adalimumab (SC)	40.0 mg	6 pens	\$14,616	\$2,436	\$73,542	14.9%	\$10,231
Certolizumab pegol (SC)	200.0 mg	3 syringe kits	\$12,132	\$4,044	\$68,232	9.9%	\$8,493
Etanercept (SC)	50.0 mg	4 syringes	\$4,872	\$1,218	\$59,953	16.4%	\$3,410
Golimumab (SC)	50.0 mg	1 syringe	\$4,520	\$4,520	\$68,955	14.5%	\$3,164
Golimumab (IV)	50.0 mg	1 vial	\$1,734	\$1,734	\$59,952	14.5%	\$1,213
Infliximab (IV)	100.0 mg	1 vial	\$1,168	\$1,168	\$37,228	8.3%	\$817
Infliximab (IV) biosimilar	100.0 mg	1 vial	\$889	\$889	\$28,332	8.3%	\$622
JAK inhibitors							
Tofacitinib (Oral)	5.0 mg	60 tablets	\$4,099	\$63	\$46,213	15.5%	\$3,891
csDMARDs							
Methotrexate	2.5 mg	100 tablets	\$236	\$2.36	\$1,139	0.0%	Not applicable
Concomitant medication:							
Prednisone	10.0 mg	1 tablet	\$0.19	\$0.19	\$69	0.0%	Not applicable

Notes: ^aAssuming full compliance, no fees, discounts or any patient out of pocket contributions. ^bBased on the compound annual growth rate for drug prices between January 2013 to January 2016. ^cDiscounts: TNFi: 30%, CD-20 directed cytolytic antibody: 15%, T-cell inhibitors: 30%, IL-6 inhibitors: 20%, JAK inhibitors: 5%.

Abbreviations: csDMARD, conventional synthetic disease-modifying antirheumatic drug; IV, intravenous; JAK, janus kinase; SC, subcutaneous; TNFi, tumor necrosis factor inhibitor; WAC, wholesale acquisition cost.

Table S2 Budget impact by cost metric in years 1–5, in (A) csDMARD-IR, (B) TNF-IR populations, (C) combination (pooled csDMARD-IR and TNF-IR), and (D) monotherapy (csDMARD-IR or TNF-IR)

Cost by metric	Year 1	Year 2	Year 3	Year 4	Year 5	Years 1–5
(A) csDMARD-IR						
DMARDs						
Base-case	\$20,254,095	\$20,824,169	\$21,474,496	\$22,205,356	\$23,026,048	\$107,784,164
Projected	\$20,226,459	\$20,764,870	\$21,378,464	\$22,066,321	\$22,836,306	\$107,272,419
Net	–\$27,636	–\$59,299	–\$96,033	–\$139,035	–\$189,742	–\$511,744
Administration						
Base-case	\$223,299	\$223,756	\$224,254	\$224,677	\$224,996	\$1,120,982
Projected	\$222,182	\$221,518	\$220,890	\$220,184	\$219,371	\$1,104,146
Net	–\$1,116	–\$2,238	–\$3,364	–\$4,494	–\$5,625	–\$16,836
Concomitant medications						
Base-case	\$8,699	\$8,717	\$8,736	\$8,752	\$8,765	\$43,668
Projected	\$8,696	\$8,712	\$8,729	\$8,743	\$8,753	\$43,634
Net	–\$3	–\$5	–\$7	–\$9	–\$12	–\$35
Monitoring						
Base-case	\$61,176	\$61,301	\$61,438	\$61,554	\$61,641	\$307,110
Projected	\$61,321	\$61,593	\$61,876	\$62,139	\$62,373	\$309,302
Net	\$145	\$291	\$438	\$585	\$732	\$2,192
Total costs						
Base-case	\$20,547,268	\$21,117,943	\$21,768,924	\$22,500,339	\$23,321,449	\$109,255,924
Projected	\$20,518,659	\$21,056,693	\$21,669,959	\$22,357,386	\$23,126,803	\$108,729,500
Net	–\$28,610	–\$61,249	–\$98,965	–\$142,953	–\$194,646	–\$526,424
(B) TNF-IR						
DMARDs						
Base-case	\$15,608,855	\$16,031,438	\$16,510,886	\$17,046,450	\$17,644,182	\$82,841,812
Projected	\$15,592,910	\$15,996,734	\$16,453,889	\$16,962,801	\$17,528,531	\$82,534,865
Net	–\$15,945	–\$34,705	–\$56,997	–\$83,649	–\$115,651	–\$306,948
Administration						
Base-case	\$228,199	\$228,667	\$229,176	\$229,608	\$229,934	\$1,145,585
Projected	\$227,058	\$226,380	\$225,738	\$225,016	\$224,186	\$1,128,379
Net	–\$1,141	–\$2,287	–\$3,438	–\$4,592	–\$5,748	–\$17,206
Concomitant medications						
Base-case	\$7,206	\$7,220	\$7,236	\$7,250	\$7,260	\$36,173
Projected	\$7,204	\$7,218	\$7,233	\$7,245	\$7,254	\$35,154
Net	–\$2	–\$2	–\$3	–\$5	–\$6	–\$9
Monitoring						
Base-case	\$55,731	\$55,846	\$55,970	\$56,075	\$56,155	\$279,777
Projected	\$55,833	\$56,050	\$56,277	\$56,485	\$56,668	\$281,313
Net	\$102	\$204	\$307	\$410	\$513	\$1,536
Total costs						
Base-case	\$15,899,992	\$16,323,171	\$16,803,268	\$17,339,384	\$17,937,532	\$84,303,347
Projected	\$15,883,006	\$16,286,381	\$16,743,137	\$17,251,548	\$17,816,639	\$83,980,711
Net	–\$16,986	–\$36,790	–\$60,131	–\$87,837	–\$120,893	–\$322,637
(C) Combination therapy (pooled csDMARD-IR and TNF-IR)						
DMARDs						
Base-case	\$36,177,639	\$37,182,732	\$38,327,255	\$39,610,950	\$41,049,549	\$192,348,125
Projected	\$36,132,484	\$37,085,458	\$38,169,098	\$39,381,082	\$40,734,673	\$191,502,794
Net	–\$45,155	–\$97,274	–\$158,157	–\$229,868	–\$314,876	–\$845,331
Administration						
Base-case	\$442,973	\$443,881	\$444,869	\$445,708	\$446,340	\$2,223,771
Projected	\$440,758	\$439,442	\$438,196	\$436,794	\$435,182	\$2,190,372
Net	–\$2,215	–\$4,439	–\$6,673	–\$8,914	–\$11,159	–\$33,399

(Continued)

Table S2 (Continued)

Cost by metric	Year 1	Year 2	Year 3	Year 4	Year 5	Years 1–5
Concomitant medications						
Base-case	\$15,932	\$15,965	\$16,000	\$16,031	\$16,053	\$79,981
Projected	\$15,929	\$15,957	\$15,989	\$16,016	\$16,035	\$79,925
Net	–\$3	–\$8	–\$11	–\$15	–\$19	–\$56
Monitoring						
Base-case	\$116,023	\$116,260	\$116,519	\$116,739	\$116,905	\$582,446
Projected	\$116,274	\$116,765	\$117,277	\$117,752	\$118,172	\$586,240
Net	\$252	\$504	\$758	\$1,013	\$1,262	\$3,794
Total costs						
Base-case	\$36,752,567	\$37,758,838	\$38,904,643	\$40,189,428	\$41,628,848	\$195,234,324
Projected	\$36,705,445	\$37,657,622	\$38,740,560	\$39,951,644	\$41,304,062	\$194,359,332
Net	–\$47,122	–\$101,216	–\$164,083	–\$237,784	–\$324,786	–\$874,992
Cost by metric	Year 1	Year 2	Year 3	Year 4	Year 5	Years 1–5
(D) Monotherapy (csDMARD-IR or TNF-IR)						
DMARDs						
Base-case	\$10,746,634	\$11,047,944	\$11,391,063	\$11,775,969	\$12,207,397	\$57,169,007
Projected	\$10,732,920	\$11,018,425	\$11,343,110	\$11,706,334	\$12,112,089	\$56,912,879
Net	–\$13,714	–\$29,518	–\$47,952	–\$69,635	–\$95,308	–\$256,127
Administration						
Base-case	\$132,892	\$133,164	\$133,461	\$133,712	\$133,902	\$667,131
Projected	\$132,228	\$131,833	\$131,459	\$131,038	\$130,555	\$657,112
Net	–\$664	–\$1,332	–\$2,002	–\$2,674	–\$3,348	–\$10,020
Concomitant medications						
Base-case	\$4,780	\$4,789	\$4,800	\$4,809	\$4,816	\$23,994
Projected	\$4,779	\$4,787	\$4,797	\$4,805	\$4,810	\$23,978
Net	–\$1	–\$2	–\$3	–\$4	–\$6	–\$17
Monitoring						
Base-case	\$5,902	\$5,914	\$5,927	\$5,938	\$5,947	\$29,628
Projected	\$6,025	\$6,161	\$6,298	\$6,434	\$6,567	\$31,486
Net	\$123	\$247	\$371	\$496	\$621	\$1,858
Total costs						
Base-case	\$10,890,208	\$11,191,811	\$11,535,251	\$11,920,429	\$12,352,061	\$57,889,760
Projected	\$10,875,951	\$11,161,206	\$11,485,664	\$11,848,611	\$12,254,022	\$57,625,454
Net	–\$14,256	–\$30,605	–\$49,586	–\$71,818	–\$98,040	–\$264,306

Abbreviations: csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; IR, inadequate response; TNF, tumor necrosis factor inhibitor.

ClinicoEconomics and Outcomes Research

Publish your work in this journal

ClinicoEconomics and Outcomes Research is an international, peer-reviewed open-access journal focusing on health technology assessment, pharmacoeconomics and outcomes research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems

organization also constitute important areas of coverage. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal>

Dovepress